Latest Research News from the Foundation for Women&#x27;s Cancer and Society of Gynecologic Oncology

What New Cancer Drugs Were Approved in 2023?

New FDA approvals in July include therapies for NSCLC, relapsed multiple myeloma, liver cancer, and B-cell malignancies.

Sonrotoclax/Zanubrutinib Generates Durable Response in R/R MCL

In this special episode of The Vitals, we ring in the New Year 2024 by combing through 2023 FDA approvals.

Chris Ryan

Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies

Adding sonrotoclax to zanubrutinib led to deep and durable response in relapsed or refractory mantle cell lymphoma, according to EHA Congress data.

Opinion: Comprehensive Genomic Profiling Is Vital for Optimizing NSCLC Care

Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.

Amanda Brink, DNP, APRN, FNP-BC, AOCNP

Q&A: Nursing Considerations From Immune Cell Effector Therapy Experts

Oncology nurses can ensure patients with non–small cell lung cancer receive the optimal treatment quickly by understanding comprehensive genomic profiling.

July FDA Oncology Approvals Include Options for NSCLC, Myeloma, and More

2025 ICE-T Conference presenters explain what nurses and APPs should take into account as immune cell effector therapies become more widely used.

Related Content

What New Cancer Drugs Were Approved in 2023?

New FDA approvals in July include therapies for NSCLC, relapsed multiple myeloma, liver cancer, and B-cell malignancies.

Sonrotoclax/Zanubrutinib Generates Durable Response in R/R MCL

In this special episode of The Vitals, we ring in the New Year 2024 by combing through 2023 FDA approvals.

Chris Ryan

Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies

Adding sonrotoclax to zanubrutinib led to deep and durable response in relapsed or refractory mantle cell lymphoma, according to EHA Congress data.

Opinion: Comprehensive Genomic Profiling Is Vital for Optimizing NSCLC Care

Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.

Amanda Brink, DNP, APRN, FNP-BC, AOCNP

Q&A: Nursing Considerations From Immune Cell Effector Therapy Experts

Oncology nurses can ensure patients with non–small cell lung cancer receive the optimal treatment quickly by understanding comprehensive genomic profiling.